Monthly Archives: November 2013

Study: Marijuana Compound Can Kill Some Cancer Cells – TIME

Posted on by

Marijuana leaf

“Compounds derived from marijuana can kill cancerous cells in patients with leukemia, according to a recent study.

The study, published in the Anticancer Research journal, was partially funded by GW Pharmaceuticals. which already produces a cannabis-derived drug to help people with multiple sclerosis. Dr. Wai Liu studied six different non-psychoactive cannabinoids (compounds derived from marijuana that don’t get the user high like its THC component does). He found that certain non-psychoactive cannabinoids “resulted in dramatic reductions in cell viability” and “caused a simultaneous arrest at all phases of the cell cycle,” according to the study summary posted online.

Leukemia will take the lives of an estimated 23,720 people this year.

This isn’t the first time marijuana has been linked to deterring cancer: In 2012, researchers at the California Pacific Medical Center in San Francisco found that CBD — a non-psychoactive chemical compound found in cannabis — can stop metastasis in some kinds of aggressive cancer. Liu told the Huffington Post that smoking cannabis is unlikely to have the same cancer-inhibiting effect.”

http://healthland.time.com/2013/10/28/study-marijuana-compounds-can-kill-some-cancer-cells/

In vivo type 1 cannabinoid receptor availability in Alzheimer’s disease.

Posted on by

“The endocannabinoid system (ECS) is an important modulatory and potentially neuroprotective homeostatic system in the brain.

  We have investigated CB1R availability in vivo in patients with AD…

 In conclusion, we found no in vivo evidence for a difference in CB1R availability in AD compared to age-matched controls.

 Taken together with recently reported in vivo CB1R changes in Parkinson’s and Huntington’s disease, these data suggest that the CB1R is differentially involved in neurodegenerative disorders.”

http://www.ncbi.nlm.nih.gov/pubmed/24189376

 

Cannabis might be a better treatment for epilepsy sufferers -msn

Posted on by

Young marijuana plants (©AP Photo/Ted S. Warren)

“Cannabis is now apparently the cure for everything from cancer,  diarrhea, bipolar disorder and Multiple sclerosis, to an ailing economy and being a smart aleck teenager. The latest chronic illness to get the 4:20 treatment is epilepsy. British scientists from the University of Reading tested a compound in pot called cannabidivarin on rats and mice with six types of epilepsy, and found it “strongly suppressed seizures” without the unpleasant side effects of current anti-epilepsy drugs. With 1 percent of the world’s population suffering from the disease, the head of the research team, Ben Whalley, says there’s a pressing need for better treatments. “It’s a chronic condition with no cure and currently, in around one-third of cases, the currently available treatments do not work, cause serious side effects and increase fatalities,” he said.”

http://now.msn.com/epilepsy-treatment-found-in-cannabis-may-prove-better-than-current-methods

Drugs group’s high hopes for epilepsy trials

Posted on by

“A cannabis-based medicine could help the world’s 50 million epileptics control their seizures after a British drugmaker today began putting a potential treatment through human clinical trials.

GW Pharmaceuticals, which already uses cannabis to make Sativex for MS sufferers, has spent five years carrying out pre-clinical research on whether a cannabis-derived compound could treat epileptics’ seizures, with fewer side effects than current drugs. 

About a third of epileptics take no medication, either because existing treatments don’t control their seizures or because they can’t tolerate the side effects.

But positive results from GW’s research mean it is putting its potential new drug, dubbed GWP42006, through Phase 1 human trials. The drugmaker grows genetically-cloned marijuana plants for the medicine in secret locations in England.

The trials announcement is “a significant milestone in the development of this novel product candidate,” said Stephen Wright, GW’s director of research.”

http://www.standard.co.uk/business/business-news/drugs-groups-high-hopes-for-epilepsy-trials-8824297.html

 

FDA approves marijuana based drug

Posted on by

“The U.S. Food and Drug Administration has approved clinical trials of a cannabis-based drug and its effects on epilepsy. The treatment, Epidiolex, is 98 percent purified cannabidiol (CBD) made by GW Pharmaceuticals based out of the U.K.  

There are around 60 known chemicals contained in cannabis called cannabinoids. Tetrahydrocannabinol, also known as THC, is the main component responsible for the drug’s psychoactive nature. CBD, however, is the second most abundant cannabinoid in the cannabis and provides medicinal benefits without the “high.” Epidiolex will come in a viscous liquid form to be dispensed from syringes. A 25 milligram per meter or 100 milligram per meter will be the two strengths made available to those in the trials.

The FDA has approved of intermediate-sized clinical trials sponsored by two doctors. Dr. Orrin Devinsky, a professor in the Department of Neurology, Neuroscience and Psychiatry in the New York University School of Medicine and director of the NYU Comprehensive Epilepsy Center, and Dr. Roberta Cilio, a pediatric neurologist at the University of California, San Francisco, are set to follow 25 patients using Epidiolex as treatment for pediatric epilepsy.

On Oct. 4, at the NYU Langone Medical Center, Devinsky led a conference entitled, “Cannabidiols: Potential Use in Epilepsy & Other Neurological Disorders.” During the affair, Devinsky and Cilio led a presentation on planned trials on CBD in children with treatment resistant epilepsy. 

The D.C. – based Marijuana Policy Project’s Communications Director Mason Tvert responded to the news of the approved trials. “We’ve long known that marijuana has a variety of medical benefits,” Tvert said. Tvert added that the federal government clearly recognizes marijuana’s medicinal benefits and it’s a shame they hindered most research of it.

Maryland’s new marijuana law came into effect on Oct. 1, but its miniscule scope won’t have much effect. It deals with a small number of patients that would enroll in state-approved clinical studies. However, with no hospitals signed up to hold these studies, no visible changes are set to occur in the near future.

Now the country will wait and see if CBD can live up to the hype, and if the epileptic patients can find any relief from their disease.”

 By Bonnie Katz

http://www.thesentinel.com/mont/news/FDA-approves-marijuana-drug10-31-2013

“Cannabis-Based Epilepsy Drug Approved For Clinical Trials” http://www.medicaljane.com/2013/10/23/cannabis-based-epilepsy-drug-approved-for-clinical-trials/

Around The World, Researchers Begin Clinical Trials of Cannabis For Epilepsy

Posted on by
 
Many patients in the U.S. have turned to tinctures and oil extracts to help control their seizures (Photo: Luis Sinco/Los Angeles Times) 
 

“While a large body of anecdotal and laboratory evidence points to cannabis as an effective treatment for epilepsy, research in humans is just beginning to catch up.

 GW Pharmaceuticals – the UK-based company behind the natural cannabis spray Sativex – announced the start of the first round of clinical trials of a new cannabis treatment for epilepsy.

In the press release, Dr. Stephen Wright, Director of Research and Development at GW, said the company has spent years testing cannabis in pre-clinical models – which include cell cultures and animals.

So far, the drug is only known as GWP42006.

“We are pleased to have advanced GWP42006 to first dose in man, a significant milestone in the development of this novel product candidate. The decision to progress into Phase 1 follows several years of highly promising pre-clinical research.”

Dr. Ben Whalley, Senior Lecturer in Pharmacology at the Reading School of Pharmacy, added, “Our research collaboration with GW over the last several years has shown that GWP42006 not only exerts significant anticonvulsant effects in a wide range of preclinical models of seizure and epilepsy but is also better tolerated compared to existing anti-epileptic drugs.”

While the company has not disclosed the ingredients in the new drug, their latest animal study – which appears in the October issue of the British Journal of Pharmacology – showed positive results with two chemicals derived from cannabis: Cannabidiol (CBD) and cannabidivarin (CBDV).

Both were found to suppress seizures and increase survival across a range of different rat models of epilepsy.”

More: http://www.leafscience.com/2013/09/20/around-world-researchers-begin-clinical-trials-cannabis-epilepsy/

Both CBD and CBDV are produced naturally by cannabis. Unlike THC, these two compounds do not get patients high.

“Both CBD and CBDV are produced naturally by cannabis. Unlike THC, these two compounds do not get patients high.”

“GW Pharmaceuticals Commences Phase 1Clinical Trial of GWP42006” (to be marketed as “Epidiolex”),”as a Potential Treatment for Epilepsy”

Posted on by

EPIDIOLEX

“GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW”) announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.

Over the last five years, GW has conducted an extensive pre-clinical cannabinoid research program in the field of epilepsy in collaboration with the University of Reading in the United Kingdom. This research has led to the emergence of a number of promising cannabinoid therapeutic candidates showing anti-epileptic effects.

GWP42006, one of the most promising of those candidates, is a non-psychoactive cannabinoid extracted from specific chemotypes of the cannabis plant which has shown the ability to treat seizures in pre-clinical models of epilepsy with significantly fewer side effects than currently approved anti-epileptic drugs1.

“We are pleased to have advanced GWP42006 to first dose in man, a significant milestone in the development of this novel product candidate. The decision to progress into Phase 1 follows several years of highly promising pre-clinical research,” stated Dr. Stephen Wright, Director of Research and Development at GW. “We believe that GWP42006 has the potential to become an important advance in the treatment of epilepsy, a condition for which there remains a substantial unmet medical need.””

More: http://www.gwpharm.com/Phase1Epilepsy.aspx

“GW Pharma Commences Phase 1 Clinical Trial Of GWP42006 For Treatment Of Epilepsy… GWP42006, is a non-psychoactive cannabinoid extracted from specific chemotypes of the cannabis plant which has shown the ability to treat seizures in pre-clinical models of epilepsy with significantly fewer side effects than currently approved anti-epileptic drugs.” http://www.nasdaq.com/article/gw-pharma-commences-phase-1-clinical-trial-of-gwp42006-for-treatment-of-epilepsy-20130918-00037

“A Study of the Safety and Tolerability of GWP42006 in Healthy Subjects…This study is currently recruiting participants.” http://clinicaltrials.gov/show/NCT01918735

“Driving directions to GW Pharma Limited and product information about EPIDIOLEX is provided. EPIDIOLEX is a product created by GW Pharma Limited in  Porton Down Science Park , Salisbury, , SP4OJR. The EPIDIOLEX  is a product related to Pharmaceutical and veterinary preparations and substances for the treatment of epilepsy, convulsions, seizures, Dravet syndrome, Lennox-Gastaut syndrome, intractable childhood epilepsy with generalized tonic-clonic seizures, generalized epilepsy with febrile seizures plus, Doose syndrome and chromosome disorders; pharmaceutical preparations and substances for the treatment of pediatric epilepsy; herbs for medicinal purposes; medicinal herbs; medicinal oils; medicinal infusions for the treatment of epilepsy; pure extracts of medicinal plants and herbs used for the treatment of epilepsy, convulsions and seizures; herb teas for medicinal purposes. The EPIDIOLEX product is now being marketed in the United States for sale. The EPIDIOLEX is in the category of  Pharmaceutical Products..

Get in contact with the owner, GW Pharma Limited of this EPIDIOLEX, or visit them at their place of business in the map. Write a review about the product with this EPIDIOLEX.

Or, contact the owner GW Pharma Limited of the  EPIDIOLEX trademark by filing a request to communicate with the Legal Correspondent   for licensing, use, and/or questions related to EPIDIOLEX. The correspondent of the EPIDIOLEX is  MICHELLE L. VISSER of RADER, FISHMAN & GRAUER PLLC, 39533 WOODWARD AVE STE 140, BLOOMFIELD HILLS, MI 48304-5098 “.

http://www.trademarkia.com/map/epidiolex-86007888.htm

Comes Now Epidiolex™ (FDA approves IND studies of CBD)

Posted on by

NYU Conference

“In response to urgent need expressed by parents of children with intractable epilepsy, the U.S. Food and Drug Administration is allowing Investigational New Drug studies of purified CBD (cannabidiol) as an anti-seizure medication. The “new drug” is being provided to physician-investigators by GW Pharmaceuticals, which has named its CBD product “Epidiolex™.”

More: http://www.beyondthc.com/comes-now-epidiolex-fda-approves-ind-studies-of-cbd/

New Cannabis Drug Approved For Trials In Children With Epilepsy

Posted on by
 (Photo: GW Pharmaceuticals)
 
 

“New Cannabis Drug Approved For Trials In Children With Epilepsy

 

A new cannabis-based drug made by GW Pharmaceuticals has been approved by the U.S. Food and Drug Administration (FDA) for two separate trials involving children with epilepsy.

The drug is made from purified cannabidiol (CBD) – a non-psychoactive compound in marijuana – and is being marketed under the name Epidiolex, reports O’Shaughnessy’s.

So far, the FDA has approved two Investigational New Drug studies of Epidiolex for pediatric epilepsy, which are being led by Orrin Devinsky, MD, at the NYU School of Medicine, and Roberta Cilio, MD, PhD, at the University of California, San Francisco (UCSF). Each will involve 25 children with epilepsy, and other studies are awaiting approval.

If all goes as planned, GW Pharmaceuticals’ Chairman Geoffrey Guy, MD, expects more studies to begin within months.

“In the coming months, if the FDA is comfortable about how things are going, there will be a number of senior epileptologists in major university centers throughout the U.S., each treating a couple of dozen patients with various epilepsies.”

GW Pharmaceuticals is best known for its cannabis-based spray called Sativex, which is approved in over 20 countries for the treatment of multiple sclerosis symptoms.

However, the company has spent recent years developing a drug for epilepsy. Preclinical studies sponsored by the company show that CBD, along with a related cannabinoid called CBDV, have the potential to reduce epileptic seizures. Anecdotal reports also suggest that CBD-rich cannabis extracts could be effective in treating epilepsy in children.

Unlike Sativex, Epidiolex is a liquid medicine that can be administered with a syringe dropper. According to the company, the drug contains more than 98 percent CBD, along with trace amounts of other cannabinoids.”

More: http://www.leafscience.com/2013/10/22/new-cannabis-drug-approved-trials-children-epilepsy/

“Comes Now Epidiolex™ (FDA approves IND studies of CBD)” http://www.beyondthc.com/comes-now-epidiolex-fda-approves-ind-studies-of-cbd/

It’s Lung Cancer Awareness Month. Please, BE AWARE:

Posted on by

A tourist looks over the city's skyline over a thin haze of pollution on a clear day in Hong Kong on February 1, 2013. Emissions from factories in southern China, which seep over Hong Kong's border, combined with local emissions from power plants and transport, generate an almost daily thick blanket of haze over the teeming metropolis.

“Air pollution causes lung cancer, World Health Organization confirms” http://www.cbsnews.com/8301-204_162-57607955/air-pollution-causes-lung-cancer-world-health-organization-confirms/

“Marijuana May Fight Lung Tumors… active ingredient in marijuana may help combat lung cancer… In lab and mouse studies, the compound, known as THC, cut lung tumor growth in half and helped prevent the cancer from spreading…” http://www.cbsnews.com/2100-500368_162-2696726.html

“Lung cancer leads all cancer deaths”  http://www.thespectrum.com/story/life/features/mesquite/2014/10/20/lung-cancer-leads-cancer-deaths/17640075/

“Air Pollution a Leading Cause of Cancer. The United Nation’s World Health Organization (WHO) has classified air pollution as a prime cause of cancer worldwide, especially in the case of lung cancer.” http://www.webmd.com/cancer/news/20131018/air-pollution-cancer

“Pot Smoking Not Linked to Lung Cancer. Study Shows No Increased Risk for Even the Heaviest Marijuana Smokers.” http://www.webmd.com/lung-cancer/news/20060523/pot-smoking-not-linked-to-lung-cancer

“Marijuana May Fight Lung Tumors… the active ingredient in marijuana may help combat lung cancer…”http://www.webmd.com/lung-cancer/news/20070417/marijuana-may-fight-lung-tumors

“WHO agency: Air pollution causes cancer. What many commuters choking on smog have long suspected has finally been scientifically validated: air pollution causes lung cancer.” http://www.abclocal.go.com/ktrk/story?section=news%2Fhealth&id=9290406

“Marijuana Compound May Fight Lung Cancer… Harvard University researchers have found that, in both laboratory and mouse studies, delta-tetrahydrocannabinol (THC) cuts tumor growth in half in common lung cancer while impeding the cancer’s ability to spread.”
http://abcnews.go.com/Health/Healthday/story?id=4506595&page=1

“Don’t Smoke? You Could Still Get Lung Cancer”  http://health.clevelandclinic.org/2014/10/dont-smoke-you-could-still-get-lung-cancer/

“Radon No. 1 lung cancer cause in nonsmokers”  http://www.rgj.com/story/life/wellness/2014/10/24/radon-lung-cancer-cause-nonsmokers/17866569/

“Air pollution causes lung cancer, World Health Organization says”  http://articles.latimes.com/2013/oct/17/science/la-sci-sn-air-pollution-causes-lung-cancer-20131017

“Smog Tied to Higher Risk of Lung Cancer, Heart Failure” http://health.usnews.com/health-news/news/articles/2013/07/10/smog-tied-to-higher-risk-of-lung-cancer-heart-failure

“Mountaintop Removal Mining Dust Linked To Increased Risk Of Lung Cancer, According to Study”  http://lungcancernewstoday.com/2014/10/20/mountaintop-removal-mining-dust-linked-increased-risk-lung-cancer-according-study/

“Study Shows Direct Connections Between Mountaintop Removal Dust Exposure and Lung Cancer”  http://wfpl.org/post/study-shows-direct-connections-between-mountaintop-removal-dust-exposure-and-lung-cancer

“Compound in chili pepper slows lung cancer tumor growth. New laboratory research shows capsaicin decrease growth of an aggressive form of lung cancer.”  http://www.teatronaturale.com/food-and-fun/health/4983-compound-in-chili-pepper-slows-lung-cancer-tumor-growth.htm

“Drinking alcohol may boost lung cancer risk” http://www.foodconsumer.org/newsite/Nutrition/Food/drinking_alcohol_and_lung_cancer_risk_1024110625.html

“Link Between Alcohol And Cancer Explained: Alcohol Activates Cellular Changes That Make Tumor Cells Spread” http://www.sciencedaily.com/releases/2009/10/091026172052.htm

“Groups seek to curb tobacco use in cancer patients… Tobacco use plays a role in 18 different cancers… Patients who use tobacco have worse outcomes and more difficult treatment… tobacco use decreases the effectiveness of chemotherapies and interferes with drug metabolism… data also shows that it decreases survival… we call on the oncology community… to provide cessation support to all cancer patients,” http://www.oncologypractice.com/oncologyreport/news/top-news/single-view/groups-seek-to-curb-tobacco-use-in-cancer-patients/1a87bf57bcccdadf01ae769c48eadce4.html

“Marijuana habit not linked to lung cancer” http://www.oncologypractice.com/oncologyreport/news/top-news/single-view/marijuana-habit-not-linked-to-lung-cancer/73840afd2cca226b9e6a9ddc7cb0d039.html

“Cannabis and tobacco smoke are not equally carcinogenic… Available scientific data, that examines the carcinogenic properties of inhaling smoke and its biological consequences, suggests reasons why tobacco smoke, but not cannabis smoke, may result in lung cancer… Furthermore, compounds found in cannabis have been shown to kill numerous cancer types including: lung cancer…”  http://www.harmreductionjournal.com/content/2/1/21

“Tobacco Smoke Causes Lung Inflammation, Promotes Lung Cancer Growth” http://www.sciencedaily.com/releases/2010/01/100119121206.htm

“Marijuana Cuts Lung Cancer Tumor Growth In Half, Study Shows”
http://www.sciencedaily.com/releases/2007/04/070417193338.htm

“Delta–9 Tetrahydrocannabinol inhibits growth and metastasis of lung cancer” http://www.thctotalhealthcare.com/delta-9-tetrahydrocannabinol-inhibits-growth-and-metastasis-of-lung-cancer-harvard-university/

“Δ-9 Tetrahydrocannabinol inhibits growth and metastasis of lung cancer.”  http://cancerres.aacrjournals.org/content/67/9_Supplement/4749.short

“Antineoplastic activity of cannabinoids. Lewis lung adenocarcinoma growth was retarded by the oral administration of delta-9-tetrahydrocannabinol, delta-8-tetrahydrocannabinol, and cannabinol (CBN)… Delta-9-THC, delta-8-THC, and cannabinol (CBN) all inhibited primary Lewis lung tumor growth….. All occur naturally in marihuana… these compounds readily cross the blood-brain barrier and do not possess many of the toxic manifestations of presently used cytotoxic agents…” http://www.ukcia.org/research/AntineoplasticActivityOfCannabinoids/index.php

“Antineoplastic activity of cannabinoids.”  http://www.ncbi.nlm.nih.gov/pubmed/1159836

“Antineoplastic: A drug used to inhibit the growth and spread of cancerous cells.. a chemotherapeutic agent that controls or kills cancer cells…” http://medical-dictionary.thefreedictionary.com/antineoplastic

“The Inhibition of DNA Synthesis by Cannabinoids. Several of the cannabinoids found in marihuana have been shown to inhibit tumor growth and increase the life-span… our in vitro observations with these cannabinoids are supported by in vivo tumor inhibition studies… Δ9-trans-tetrahydrocannabinol demonstrated the least toxicity of all inhibitory cannabinoids in vivo…” http://cancerres.aacrjournals.org/content/36/1/95.short

“Inhibition: “arrest or restraint of a process… Something that restrains, blocks, or suppresses… (in chemistry) the stopping or slowing of the rate of a chemical reaction.” http://medical-dictionary.thefreedictionary.com/inhibition

“Effects of delta9-tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture… We found a dose-related decrease in DNA synthesis in transformed cell cultures treated with delta9-tetrahydrocannabinol (delta9-THC)… delta9-THC inhibited DNA synthesis…” http://www.ncbi.nlm.nih.gov/pubmed/943561

“In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis lung carcinomas. Cannabinoids represent a novel class of drugs active in increasing the life span mice carrying Lewis lung tumors and decreasing primary tumor size…” http://www.ncbi.nlm.nih.gov/pubmed/616322

“Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy… Symptom scores were significantly better for patients on nabilone for nausea, retching and vomiting. Fewer subjects vomited with nabilone and the number of vomiting episodes was lower; no patients on nabilone required additional parenteral anti-emetic. More patients preferred nabilone for anti-emetic control… Nabilone is an effective oral anti-emetic drug for moderately toxic chemotherapy, but the range and unpredictability of its side-effects warrant caution in its use.” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011510/

Antiemetic: “preventing or alleviating nausea and vomiting…” http://medical-dictionary.thefreedictionary.com/antiemetic
“Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. The antiemetic effect of oral nabilone, a synthetic cannabinoid, was compared to oral slow-release capsules of prochlorperazine… Nabilone appeared to be the more effective antiemetic…” http://www.ncbi.nlm.nih.gov/pubmed/6250699
“Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. Two double-blind, crossover trials comparing the antiemetic effectiveness of nabilone, a new synthetic cannabinoid, with that of prochlorperazine were conducted in patients with severe nausea and vomiting associated with anticancer chemotherapy… patients clearly favored nabilone…” http://www.ncbi.nlm.nih.gov/pubmed/375088
“Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial… Nabilone appears to be a safe, effective, and well-tolerated antiemetic drug for children receiving cancer chemotherapy. Although major side effects may occur at higher dosages, nabilone is preferable to prochlorperazine because of improved efficacy.” http://www.ncbi.nlm.nih.gov/pubmed/3035479
“Nabilone: an effective antiemetic in patients receiving cancer chemotherapy… Eighty evaluable patients receiving chemotherapy were entered on a random prospective double-blind study to evaluate the effecti…veness of nabilone, a synthetic cannabinoid, compared to prochlorperazine… Sixty patients (75 per cent) reported nabilone to be more effective than prochlorperazine for relief of nausea and vomiting.” http://www.ncbi.nlm.nih.gov/pubmed/6271844
“Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. Anecdotal accounts suggested that smoking marihuana decreases the nausea and vomiting associated with cancer chemotherapeutic agents. Oral delta-9-tetrahydrocannabinol was compared with placebo in a controlled, randomized, “double-blind” experiment… For all patients an antiemetic effect was observed… No patient vomited while experiencing a subjective “high”. Oral tetrahydrocannabinol has antiemetic properties and is significantly better than a placebo in reducting vomiting caused by chemotherapeutic agents.” http://www.ncbi.nlm.nih.gov/pubmed/1099449
“… a randomized, double-blind, placebo-controlled trial of oral and smoked delta-9-tetrahydrocannabinol (THC) as an antiemetic… Delta-9-tetrahydrocannabinol was significantly more effective than placebo in reducing the number of vomiting and retching episodes, degree of nausea, duration of nausea, and volume of emesis… Delta-9-tetrahydrocannabinol appears to have significant antiemetic properties…” http://www.ncbi.nlm.nih.gov/pubmed/293141
“Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis… The antiemetic effect of THC appeared to be more efficacious… Tetrahydrocannabinol appears to offer significant control of nausea in most patients and exceeding by far that provided by prochlorperazine.”
http://www.ncbi.nlm.nih.gov/pubmed/6254456
“Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine… THC appeared to be more efficacious in controlling the emesis… THC appears to offer significant control of nausea in most patients…” http://www.ncbi.nlm.nih.gov/pubmed/6271846
“Delta-9-tetrahydrocannabinol as an antiemetic… THC appears to be an effective antiemetic in cancer patients undergoing chemotherapy… THC has been found consistently more effective than placebo and at least as effective as prochlorperazine… THC’s effectiveness has exceeded that of the phenothiazines.” http://www.ncbi.nlm.nih.gov/pubmed/6269423
“Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy… This study confirms the usefulness of THC in patients whose chemotherapy-induced nausea and vomiting is refractory to other standard antiemetics.” http://www.ncbi.nlm.nih.gov/pubmed/2847994

“Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1.”  http://www.ncbi.nlm.nih.gov/pubmed/22198381

“Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1.” http://www.ncbi.nlm.nih.gov/pubmed/19914218

“Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells” http://www.ncbi.nlm.nih.gov/pubmed/20668920

“CYCLOOXYGENASE-2 AND PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR γ CONFER CANNABIDIOL-INDUCED APOPTOSIS OF HUMAN LUNG CANCER CELLS.” http://www.ncbi.nlm.nih.gov/pubmed/23220503 

“Apoptosis: programmed cell death at a molecular level.” http://www.ncbi.nlm.nih.gov/pubmed/12833244

“WHO agency says air pollution causes lung cancer” http://www.foxnews.com/health/2013/10/17/who-agency-says-air-pollution-causes-lung-cancer/

“Marijuana Does Not Raise Lung Cancer Risk” http://www.foxnews.com/story/0,2933,196678,00.html

“Marijuana May Fight Lung Tumors… marijuana may help combat lung cancer… In lab and mouse studies, the compound, known as THC, cut lung tumor growth in half and helped prevent the cancer from spreading, says Anju Preet, PhD, a Harvard University researcher in Boston…”http://www.foxnews.com/story/2007/04/18/marijuana-may-fight-lung-tumors/

“Air pollution causes lung cancer, WHO agency announces. Experts at the International Agency for Research on Cancer, an agency of the World Health Organization, have concluded that exposure to outdoor air pollution.causes lung cancer and increases the risk for bladder cancer.” http://www.nbcnews.com/video/nightly-news/53309399/#53309399

“Marijuana Compound Fights Cancer; Human Trials Next.
Research shows component in medical cannabis fights cancer.” http://www.nbcbayarea.com/news/local/Marijuana-Compound-Fights-Cancer-Human-Trials-Next-170406116.html

“The endocannabinoid system and cancer: therapeutic implication… Identification of safe and effective treatments to manage and improve cancer therapy is critical to improve quality of life and reduce unnecessary suffering in cancer patients. In this regard, cannabis-like compounds offer therapeutic potential for the treatment of… cancer… anti-cancer properties of cannabinoids…” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165955/

“The endocannabinoid system in the cancer therapy: an overview.” http://www.ncbi.nlm.nih.gov/pubmed/21428888

“The endocannabinoid signaling system in cancer.”  http://www.ncbi.nlm.nih.gov/pubmed/23602129

“Changes in the Endocannabinoid System May Give Insight into new and Effective Treatments for Cancer” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791688/

“Endocannabinoid system modulation in cancer biology and therapy.” http://www.ncbi.nlm.nih.gov/pubmed/19559362

“The endocannabinoid system in cancer-potential therapeutic target?” http://www.ncbi.nlm.nih.gov/pubmed/18249558

“Targeting the endocannabinoid system for the treatment of cancer–a practical view.” http://www.ncbi.nlm.nih.gov/pubmed/20370711

“The endocannabinoid system and its therapeutic exploitation… since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs.” http://www.ncbi.nlm.nih.gov/pubmed/15340387

“The endocannabinoid system as a target for the development of new drugs for cancer therapy… evidence has accumulated indicating that stimulation of cannabinoid receptors by either THC or the endocannabinoids influence the intracellular events controlling the proliferation and apoptosis of numerous types of cancer cells, thereby leading to anti-tumour effects both in vitro and in vivo. This evidence is reviewed here and suggests that future anti-cancer therapy might be developed from our knowledge of how the endocannabinoid system controls the growth and metastasis of malignant cells.”
http://www.ncbi.nlm.nih.gov/pubmed/12723496

“Cannabinoid receptor systems: therapeutic targets for tumour intervention… there is now a genuine expectation that the manipulation of cannabinoid receptor systems may have therapeutic potential for a diverse range of human diseases… demonstrated antitumour actions of cannabinoids indicates possible avenues for the future development of cannabinoids as antitumour agents.”
http://www.ncbi.nlm.nih.gov/pubmed/14640910

“Cannabinoid-associated cell death mechanisms in tumor models… cannabinoids (the active components of Cannabis sativa)… in addition to their inhibitory effects on tumor growth and migration, angiogenesis and metastasis… these compounds induce different pathways of cell death… death mechanisms induced by cannabinoids… we analyze the pathways triggered by cannabinoids to induce apoptosis or autophagy… the results reported here suggest that the exploration of molecular mechanisms induced by cannabinoids in cancer cells can contribute to the development of safe and effective treatments in cancer therapy.” http://www.ncbi.nlm.nih.gov/pubmed/22614735

“Towards the use of cannabinoids as antitumour agents.. cannabinoids (the active components of marijuana and their derivatives) can reduce tumour growth and progression in animal models of cancer, in addition to their well-known palliative effects on some cancer-associated symptoms.”
http://www.ncbi.nlm.nih.gov/pubmed/22555283

“Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide…only limited therapeutic treatments are available. Hence, we investigated the role of cannabinoid receptors, CB1 and CB2, as novel therapeutic targets against NSCLC…. Overall, our results indicate a novel role for cannabinoid receptors CB1 and CB2 in NSCLC growth and metastasis… These results suggest that CB1 and CB2 could be used as novel therapeutic targets against NSCLC.”
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025486/

“Cannabinoid receptors as therapeutic targets.”
http://www.ncbi.nlm.nih.gov/pubmed/16402900

“Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis… Our findings indicate that CB1 receptor agonists might be used therapeutically to retard tumor growth in vivo by inhibiting at once tumor growth, angiogenesis, and metastasis.” http://www.ncbi.nlm.nih.gov/pubmed/12958205

“Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Human tissues express cannabinoid CB(1) and CB(2) receptors that can be activated by endogenously released ‘endocannabinoids’ or exogenously administered compounds in a manner that reduces the symptoms or opposes the underlying causes of several disorders in need of effective therapy. Three medicines that activate cannabinoid CB(1)/CB(2) receptors are now in the clinic: Cesamet (nabilone), Marinol (dronabinol; Δ(9)-tetrahydrocannabinol (Δ(9)-THC)) and Sativex (Δ(9)-THC with cannabidiol)… several possible additional therapeutic targets for cannabinoid receptor agonists. These include other kinds of pain, epilepsy, anxiety, depression, Parkinson’s and Huntington’s diseases, amyotrophic lateral sclerosis, stroke, CANCER, drug dependence, glaucoma, autoimmune uveitis, osteoporosis, sepsis, and hepatic, renal, intestinal and cardiovascular disorders.”
http://www.ncbi.nlm.nih.gov/pubmed/23108552

“Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Time-lapse microscopy of human lung cancer cells showed t…hat the endogenous cannabinoid anandamide (AEA), the phyto-cannabinoid Delta-9-tetrahydrocannabinol (THC) and a synthetic cannabinoid HU 210 all caused morphological changes characteristic of apoptosis.” http://www.ncbi.nlm.nih.gov/pubmed/17931597

“Programmed Cell Death (Apoptosis)” http://www.ncbi.nlm.nih.gov/books/NBK26873/

“Δ9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo…Tumor samples from THC-treated animals revealed antiproliferative and antiangiogenic effects of THC. Our study suggests that cannabinoids like THC should be explored as novel therapeutic molecules in controlling the growth and metastasis of certain lung cancers.” http://www.nature.com/onc/journal/v27/n3/abs/1210641a.html

“Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Cannabinoids (the active components of Cannabis sativa)… evidence suggests that agonists of cannabinoid receptors expressed by tumour cells may offer a novel strategy to treat cancer… use of cannabinoid agonists for cancer therapy, not only as palliative but also as curative drugs.” http://www.ncbi.nlm.nih.gov/pubmed/19285265

http://www.thctotalhealthcare.com/category/lung-cancer/